Clinical trials: Refractory Reflux Esophagitis
Refractory Reflux Esophagitis
Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole
The research aims to investigate whether trimebutine maleate combined with rabeprazole can improve the clinical efficacy in patients With refractory Los Angeles grade A or B reflux esophagitis .
- Trial name
- rRE (NCT02986685)
- Testing
- Trimebutine Maleate, rabeprazole
- Where
- China
- Sponsor
- Xijing Hospital of Digestive Diseases
GERD, Reflux
Role of ARMA in Selective Subset of Refractory GERD Patients.
To study the role of a novel endoscopic treatment technique (ARMA) in GERD patients who doesn't respond to PPI therapy (Proton Pump Inhibitor).
- Conditions
- GERD, Reflux, Reflux Esophagitis
- Trial name
- NCT05899491
- Testing
- ARMA, UGI Endoscopy
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Asian Institute of Gastroenterology, India
Gastro Esophageal Reflux, Barrett Esophagus
Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)
Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)
- Conditions
- Gastro Esophageal Reflux, Barrett Esophagus, Erosive Esophagitis
- Trial name
- NCT03228407
- Testing
- Confocal endomicroscopy, Endoscopic biopsies, Mucosal impedance (MI)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- McGuire Research Institute
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Refractory Reflux Esophagitis
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.
- Trial name
- NCT00770913
- Testing
- E3810
- Where
- 54 sites in Japan
- Volunteers
- 337 people
- Sponsor
- Eisai Co., Ltd.
Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
Background: Up to 40% of patients who are treated with PPIs for symptoms that are thought to be due to GERD experience only incomplete relief of their symptoms.
- Trial name
- NCT01404832
- Testing
- Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Dallas VA Medical Center
Reflux Esophagitis
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.
- Trial name
- NCT01860482
- Testing
- Newrabell® Tablet 10mg
- Where
- 2 sites in South Korea
- Volunteers
- 39 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Refractory Reflux Esophagitis
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis
- Trial name
- NCT01321567
- Testing
- rabeprazole sodium
- Where
- 447 sites in Japan
- Volunteers
- 2,157 people
- Sponsor
- Eisai Co., Ltd.
Gastroparesis
Domperidone for Refractory Gastrointestinal Disorders
The purpose of this study is to prescribe oral domperidone for subjects with gastrointestinal disorders who have failed or suffered adverse effects from standard medical treatment.
- Trial name
- NCT00777439
- Testing
- Domperidone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Arnold, George, M.D.